BRIEF published on 06/17/2025 at 07:05, 1 year ago Innate Pharma participera à des conférences d'investisseurs clés Biotechnologie Immunothérapie Soins De Santé Conférences D'investisseurs Innate Pharma
PRESS RELEASE published on 06/17/2025 at 07:00, 1 year ago Inside Information / Other news releases Innate Pharma to participate in H.C. Wainwright and Wolfe Research healthcare conferences showcasing their innovative immunotherapy approaches. Global biotech company expanding portfolio Biotechnology Immunotherapy Clinical-stage Innate Pharma Healthcare Conferences
BRIEF published on 06/13/2025 at 07:05, 1 year ago Innate Pharma's IPH6501 Shows Potential in Lymphoma Treatment Innate Pharma Preclinical Results IPH6501 Lymphoma R-CHOP
BRIEF published on 06/13/2025 at 07:05, 1 year ago L'IPH6501 d'Innate Pharma montre un potentiel dans le traitement du lymphome Innate Pharma Résultats Précliniques IPH6501 R-CHOP Lymphome
PRESS RELEASE published on 06/13/2025 at 07:00, 1 year ago Inside Information / Other news releases Innate Pharma highlights preclinical antitumor activity of IPH6501 in DLBCL and FL at the 2025 EHA Congress, presenting potent efficacy in in vitro and in vivo models with R-CHOP combination Preclinical Data EHA Congress Innate Pharma Antitumor Activity IPH6501
BRIEF published on 05/13/2025 at 07:05, 1 year 1 month ago Innate Pharma publie ses résultats du premier trimestre 2025 Résultats Financiers Essais Cliniques Innate Pharma Investissement Sanofi Lacutamab FDA
BRIEF published on 05/13/2025 at 07:05, 1 year 1 month ago Innate Pharma Reports First Quarter 2025 Results Financial Results Clinical Trials Innate Pharma Sanofi Investment Lacutamab FDA
PRESS RELEASE published on 05/13/2025 at 07:00, 1 year 1 month ago Informations privilégiées / Communiqué sur comptes, résultats Innate Pharma annonce ses résultats financiers du premier trimestre 2025 et les avancées de son portefeuille, incluant des investissements et des études cliniques. Une conférence téléphonique est prévue à 14h00 CEST Résultats Financiers Conférence Téléphonique Portefeuille Études Cliniques Innate Pharma
PRESS RELEASE published on 05/13/2025 at 07:00, 1 year 1 month ago Inside Information / News release on accounts, results Innate Pharma reports Q1 2025 business update with €15 million investment by Sanofi, FDA Breakthrough Therapy Designation for lacutamab, and cash position of €72.5 million FDA Financial Results Sanofi Innate Pharma Q1 2025
BRIEF published on 05/02/2025 at 15:27, 1 year 1 month ago Sanofi augmente sa participation dans Innate Pharma Capital Actions Franchissement De Seuils Sanofi Innate Pharma
Published on 06/26/2026 at 22:15, 30 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/26/2026 at 14:05, 8 hours 40 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 8 hours 45 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 9 hours 45 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 19:50, 2 hours 55 minutes ago Name Change Completed for C Capital's Swiss Listed Entity, Ticker Symbol CCAP Goes Live
Published on 06/26/2026 at 19:10, 3 hours 35 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/26/2026 at 18:04, 4 hours 41 minutes ago Turkiye Garanti Bankasi A.S.: Bond, subordinated debts, that can be included in the equity calculation debt instrument issuance CMB Application
Published on 06/26/2026 at 18:00, 4 hours 45 minutes ago PSP Swiss Property has sold the Richtipark in Wallisellen. The EBITDA guidance for the 2026 financial year has been increased.
Published on 06/26/2026 at 18:00, 4 hours 45 minutes ago VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M
